AstraZeneca reported a phase III failure for its ATTR-CM drug Wainua, shifting attention to competitors in this rare heart ...
Investor's Business Daily on MSN
Why AstraZeneca crashed 8%, leading three rivals, including Pfizer, to jump
AstraZeneca stock crashed Thursday after its Ionis-partnered treatment for a rare heart disease failed in Phase 3 testing.
A U.S. appeals court on Thursday upheld a ruling for AstraZeneca against allegations that its ​blockbuster lung-cancer drug Tagrisso infringed patents owned by ‌Pfizer subsidiary Wyeth.
Pfizer PFE and AstraZeneca AZN are two global pharmaceutical leaders with a commanding presence in oncology. For Pfizer, oncology is a key growth driver, accounting for roughly 27% of total company ...
LONDON (Reuters) -Wall Street is looking to U.S. drugmaker Eli Lilly and Anglo-Swedish rival AstraZeneca as the potential next in line after Pfizer struck a deal with Donald Trump's administration to ...
Pfizer PFE and AstraZeneca AZN are global pharmaceutical leaders with a strong presence in oncology. For Pfizer, oncology is ...
Good news for Pfizer could be good news for AstraZeneca, for two reasons. First, President Trump hinted in the press conference earlier this week that other deals similar to Pfizer's could be on the ...
Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.
Shares of AstraZeneca (NASDAQ: AZN) have jumped more than 10% this week. On Monday, the British drugmaker reported positive results from a clinical study of Enhertu in treating HER2-positive early ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results